TACSTD2 and cancer: Moreover, to determine the pharmacologic dependency of current antiandrogen therapy on GSE1/TACSTD2 signaling, using the Cancer Dependency Map platform (https://depmap.org/portal/, accessed on 28 December 2020), we demonstrated that enzalutamide sensitivity in treated 22RV1 (primary), DU145 (metastatic), PC3 (metastatic), and LNCaP clone FGC (metastatic) cell lines was inversely correlated with GSE1 expression (Pearson rho = −0.78, p = 0.43), but positively correlated with TACSTD2 expression (Pearson rho = 0.59, p = 0.60) (Figure 6C).